View in EDS

Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy Participants.

Saved in:
Bibliographic Details
Title: Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy Participants.
Authors: Hoch M; Novartis Biomedical Research, Basel, Switzerland. matthias.hoch@novartis.com., Taylor AJ; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Huth F; Novartis Biomedical Research, Basel, Switzerland., Jamalapuram S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Loisios-Konstantinidis I; Novartis Biomedical Research, Basel, Switzerland., Quinlan M; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Kranidi A; Novartis Ireland Limited, Dublin, Ireland., Coleman D; Novartis Pharma AG, Basel, Switzerland., Espurz N; Novartis Pharma AG, Basel, Switzerland., Bellibas SE; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Pierre AS; Novartis Biomedical Research, Basel, Switzerland.
Source: Clinical pharmacokinetics [Clin Pharmacokinet] 2026 May; Vol. 65 (5), pp. 709-718. Date of Electronic Publication: 2026 Mar 17.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41845155
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy Participants.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hoch+M%22">Hoch M</searchLink>; Novartis Biomedical Research, Basel, Switzerland. matthias.hoch@novartis.com.<br /><searchLink fieldCode="AU" term="%22Taylor+AJ%22">Taylor AJ</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Huth+F%22">Huth F</searchLink>; Novartis Biomedical Research, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Jamalapuram+S%22">Jamalapuram S</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Loisios-Konstantinidis+I%22">Loisios-Konstantinidis I</searchLink>; Novartis Biomedical Research, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Quinlan+M%22">Quinlan M</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Kranidi+A%22">Kranidi A</searchLink>; Novartis Ireland Limited, Dublin, Ireland.<br /><searchLink fieldCode="AU" term="%22Coleman+D%22">Coleman D</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Espurz+N%22">Espurz N</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bellibas+SE%22">Bellibas SE</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Pierre+AS%22">Pierre AS</searchLink>; Novartis Biomedical Research, Basel, Switzerland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227606849%22">Clinical pharmacokinetics</searchLink> [Clin Pharmacokinet] 2026 May; Vol. 65 (5), pp. 709-718. <i>Date of Electronic Publication: </i>2026 Mar 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22%22"> </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>7606849 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1179-1926 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203125963%22">03125963 </searchLink><i>NLM ISO Abbreviation: </i>Clin Pharmacokinet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41845155
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40262-026-01629-1
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 709
    Titles:
      – TitleFull: Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy Participants.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hoch M
      – PersonEntity:
          Name:
            NameFull: Taylor AJ
      – PersonEntity:
          Name:
            NameFull: Huth F
      – PersonEntity:
          Name:
            NameFull: Jamalapuram S
      – PersonEntity:
          Name:
            NameFull: Loisios-Konstantinidis I
      – PersonEntity:
          Name:
            NameFull: Quinlan M
      – PersonEntity:
          Name:
            NameFull: Kranidi A
      – PersonEntity:
          Name:
            NameFull: Coleman D
      – PersonEntity:
          Name:
            NameFull: Espurz N
      – PersonEntity:
          Name:
            NameFull: Bellibas SE
      – PersonEntity:
          Name:
            NameFull: Pierre AS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2026 May
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1179-1926
          Numbering:
            – Type: volume
              Value: 65
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Clinical pharmacokinetics
              Type: main
ResultId 1